Advanced Solid Formulations For Vulvovaginal Candidiasis

Conte, Júlia; Parize, Alexandre Luís; Caon, Thiago

doi:10.1007/s11095-022-03441-5

Cited by 7 publications

(4 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the pharmacological activities of these two molecules have already been reported, and our research group has already demonstrated their antifungal activity [24][25][26]. Recent studies in pharmaceutical technology have focused on the development of drug delivery systems capable of improving the distribution and retention of drugs in the vaginal mucous membrane, providing greater patient acceptability, and a sustained release of the drug also, such as increased activity and reduced toxicity [20,27].…”

Section: Introductionmentioning

confidence: 96%

“…Therefore, antifungal therapies, after oral administration, are also limited due to their toxicity, side effects in pregnant women, and drug interactions. For this reason, topical treatments are often more advantageous than oral drugs [18][19][20]. Local administration of antimicrobials has also been considered to allow greater control of drug administration and reduce or avoid undesirable systemic adverse effects [20,21].…”

Section: Introductionmentioning

confidence: 99%

“…For this reason, topical treatments are often more advantageous than oral drugs [18][19][20]. Local administration of antimicrobials has also been considered to allow greater control of drug administration and reduce or avoid undesirable systemic adverse effects [20,21].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Bioprospecting, Synergistic Antifungal and Toxicological Aspects of the Hydroxychalcones and Their Association with Azole Derivates against Candida spp. for Treating Vulvovaginal Candidiasis

Fernandes,

Ogasawara,

Medina-Alarcón

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Vulvovaginal candidiasis (VVC) remains a prevalent fungal disease, characterized by challenges, such as increased fungal resistance, side effects of current treatments, and the rising prevalence of non-albicans Candida spp. naturally more resistant. This study aimed to propose a novel therapeutic approach by investigating the antifungal properties and toxicity of 2-hydroxychalcone (2-HC) and 3′-hydroxychalcone (3′-HC), both alone and in combination with fluconazole (FCZ) and clotrimazole (CTZ). A lipid carrier (LC) was also developed to deliver these molecules. The study evaluated in vitro anti-Candida activity against five Candida species and assessed cytotoxicity in the C33-A cell line. The safety and therapeutic efficacy of in vivo were tested using an alternative animal model, Galleria mellonella. The results showed antifungal activity of 2-HC and 3′-HC, ranging from 7.8 to 31.2 as fungistatic and 15.6 to 125.0 mg/L as fungicide effect, with cell viability above 80% from a concentration of 9.3 mg/L (2-HC). Synergistic and partially synergistic interactions of these chalcones with FCZ and CTZ demonstrated significant improvement in antifungal activity, with MIC values ranging from 0.06 to 62.5 mg/L. Some combinations reduced cytotoxicity, achieving 100% cell viability in many interactions. Additionally, two LCs with suitable properties for intravaginal application were developed. These formulations demonstrated promising therapeutic efficacy and low toxicity in Galleria mellonella assays. These results suggest the potential of this approach in developing new therapies for VVC.

show abstract

Section: Introductionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bioprospecting, Synergistic Antifungal and Toxicological Aspects of the Hydroxychalcones and Their Association with Azole Derivates against Candida spp. for Treating Vulvovaginal Candidiasis

Fernandes,

Ogasawara,

Medina-Alarcón

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…Therefore, controlled release systems may be promising for reducing the inconveniences of administering CUR and MCZ. These new delivery systems have also been studied to reduce doses and administration frequency, minimize adverse effects, and improve patient compliance [ 15 ]. Ureasil–polyether hybrid materials stand out for their mechanical strength, easy manipulation, biocompatibility, and the ability to incorporate high quantities of hydrophilic or lipophilic drugs and control their release profile.…”

Section: Introductionmentioning

confidence: 99%

The Efficacy of Hybrid Vaginal Ovules for Co-Delivery of Curcumin and Miconazole against Candida albicans

Bezerra,

y Araújo,

Alves-Júnior

et al. 2024

Pharmaceutics

View full text Add to dashboard Cite

Curcumin (CUR) is a natural compound that can be combined with miconazole (MCZ) to improve vulvovaginal candidiasis (VVC) caused by Candida albicans treatment’s efficacy. This study aimed to develop ureasil–polyether (U-PEO) vaginal ovules loaded with CUR and MCZ for the treatment of VVC. Physicochemical characterization was performed by thermogravimetry (TGA), differential thermal analysis (DTA), Fourier transform infrared spectroscopy (FTIR), and in vitro release. Antifungal assays were used to determine minimum inhibitory concentrations (MICs) and synergism between CUR and MCZ, and the activity of U-PEO ovules were performed by microdilution and agar diffusion. TGA results showed high thermal stability of the hybrid ovules. In DTA, the amorphous character of U-PEO and a possible interaction between CUR and MCZ were observed. FTIR showed no chemical incompatibility between the drugs. In vitro release resulted in 80% of CUR and 95% of MCZ released within 144 h. The MICs of CUR and MCZ were 256 and 2.5 µg/mL, respectively. After combining the drugs, the MIC of MCZ decreased four-fold to 0.625 µg/mL, while that of CUR decreased eight-fold to 32 µg/mL. Synergism was confirmed by the fractional inhibitory concentration index (FICI) equal to 0.375. U-PEO alone showed no antifungal activity. U-PEO/MCZ and U-PEO/CUR/MCZ ovules showed the greatest zones of inhibition (≥18 mm). The results highlight the potential of the ovules to be administered at a lower frequency and at reduced doses compared to available formulations.

show abstract

Mitigating a widespread burden: Chitosan hydrogels and derivatives as an ecologically responsible delivery approach for vulvovaginal candidiasis

Basawa,

Kabra,

Raval

2024

Carbohydrate Polymer Technologies and Applications

View full text Add to dashboard Cite

Advanced Solid Formulations For Vulvovaginal Candidiasis

Cited by 7 publications

References 93 publications

Bioprospecting, Synergistic Antifungal and Toxicological Aspects of the Hydroxychalcones and Their Association with Azole Derivates against Candida spp. for Treating Vulvovaginal Candidiasis

Bioprospecting, Synergistic Antifungal and Toxicological Aspects of the Hydroxychalcones and Their Association with Azole Derivates against Candida spp. for Treating Vulvovaginal Candidiasis

The Efficacy of Hybrid Vaginal Ovules for Co-Delivery of Curcumin and Miconazole against Candida albicans

Mitigating a widespread burden: Chitosan hydrogels and derivatives as an ecologically responsible delivery approach for vulvovaginal candidiasis

Contact Info

Product

Resources

About